Research and Markets: Global Monoclonal Antibodies Market 2011-2015 with Roche Holding Ltd., Abbott Laboratories Johnson and Johnson Market Leaders

<0> Research and Markets: Global Monoclonal Antibodies Market 2011-2015 with Roche Holding Ltd., Abbott Laboratories Johnson and Johnson Market Leaders </0>

<0> Research and MarketsLaura Wood, Senior Manager.U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of the report to their offering.

TechNavio's analysts forecast the Global Monoclonal Antibodies market to grow at a CAGR of 10.6 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing prevalence of cancer. The Global Monoclonal Antibodies market has also been witnessing the trend of the increasing use of monoclonal antibodies in the development of personalized medicines. However, the patent expiration of top-selling monoclonal antibody drugs could pose a challenge to the growth of this market.

The key vendors dominating this market space are Roche Holding Ltd., Abbott Laboratories, Johnson and Johnson, and Merck and Co. Inc.

The other vendors mentioned in the report are Novartis International AG, Biogen Idec Inc., Bristol Myers Squibb Co., Amgen Inc., AstraZeneca plc, Eli Lilly, UCB S.A., Elan Corporations Plc, Human Genome Sciences Inc., Daiichi Sankyo, GlaxoSmithKline plc, Pfizer Inc., Eisai Co. Ltd., Bayer AG, and Alexion Pharmaceuticals.

Commenting on the report, an analyst from TechNavio's Healthcare team said: ''The development of personalized medicines has become a major trend in the Global Monoclonal Antibodies market. As the biological make-up of every person is different, the same medicine cannot be used to treat the same disease in different patients. This is because the cause of the same disease might be different in different patients. For instance, there are many causes of breast cancer. One of the main causes of breast cancer is a high concentration of an abnormal form of the growth factor Her2. In 2004, Roche, a leader in the development of personalized medicines, produced a genetically-engineered drug (a monoclonal antibody) to block the action of this growth factor.''

According to the report, one of the key drivers is the increasing prevalence of cancer. Monoclonal antibodies are more effective in the treatment of cancer than pharmaceutical drugs and chemotherapies. Hence, the worldwide increase in the prevalence of cancer has increased the revenue generation of the Global Monoclonal Antibodies market.

For more information visit

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.